Literature DB >> 1686813

Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to normal common marmosets.

P A Löschmann1, L A Smith, K W Lange, P Jaehnig, P Jenner, C D Marsden.   

Abstract

In normal common marmosets administration of the D-1/D-2 agonist apomorphine or the selective D-2 agonist quinpirole caused a dose-dependent increase in motor activity and induced stereotyped behaviour. Both the selective D-2 antagonist raclopride and the selective D-1 antagonist SCH 23390 inhibited normal locomotor activity and induced catalepsy. Quinpirole- and apomorphine-induced motor activity were potently inhibited by pretreatment with raclopride. The effects of quinpirole, but not apomorphine, were weakly inhibited by SCH 23390. The selective D-1 partial agonist SKF 38393 decreased motor activity and did not induce grooming, oral movements or other behaviours. SKF 38393 inhibited motor activity induced by the administration of quinpirole but did not alter apomorphine-induced motor behaviour. Locomotor activity in normal common marmosets appears to be mediated mainly via D-2 systems. In contrast to rodents, administration of SKF 38393 does not induce behavioural activation and there does not appear to be a facilitating effect of D-1 systems on D-2 function in the normal common marmoset. However, the ability of both SKF 38393 and SCH 23390 to inhibit quinpirole locomotor activity suggests some interaction between D-1 and D-2 systems to occur in this species.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1686813     DOI: 10.1007/bf02244422

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  25 in total

Review 1.  Multiple receptors for dopamine.

Authors:  J W Kebabian; D B Calne
Journal:  Nature       Date:  1979-01-11       Impact factor: 49.962

2.  The D1 agonist SKF 38393 inhibits the antiparkinsonian activity of the D2 agonist LY 171555 in the MPTP-treated marmoset.

Authors:  M Nomoto; P Jenner; C D Marsden
Journal:  Neurosci Lett       Date:  1988-11-11       Impact factor: 3.046

3.  Antiparkinsonian activity of CY 208-243, a partial D-1 dopamine receptor agonist, in MPTP-treated marmosets and patients with Parkinson's disease.

Authors:  J A Temlett; N P Quinn; P G Jenner; C D Marsden; E Pourcher; A M Bonnet; Y Agid; R Markstein; X Lataste
Journal:  Mov Disord       Date:  1989       Impact factor: 10.338

4.  Assessment of grooming and other behavioural responses to the D-1 dopamine receptor agonist SK & F 38393 and its R- and S-enantiomers in the intact adult rat.

Authors:  A G Molloy; J L Waddington
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

5.  Stereotyped behaviour in response to the selective D-2 dopamine receptor agonist RU 24213 is enhanced by pretreatment with the selective D-1 agonist SK&F 38393.

Authors:  M Mashurano; J L Waddington
Journal:  Neuropharmacology       Date:  1986-08       Impact factor: 5.250

6.  Antiparkinsonian activity of (+)-PHNO in the MPTP-treated common marmoset.

Authors:  M Nomoto; S Stahl; P Jenner; C D Marsden
Journal:  Mov Disord       Date:  1987       Impact factor: 10.338

7.  Dopaminergic behaviour stereospecific promoted by the D1 agonist R-SK & F 38393 and selectively blocked by the D1 antagonist SCH 23390.

Authors:  A G Molloy; J L Waddington
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

8.  Dopamine-mediated behaviours produced in naive mice by bromocriptine plus SKF 38393.

Authors:  D M Jackson; S B Ross; M Hashizume
Journal:  J Pharm Pharmacol       Date:  1988-03       Impact factor: 3.765

9.  Comparison of the distribution of D-1 and D-2 dopamine receptors in the rat brain.

Authors:  J K Wamsley; D R Gehlert; F M Filloux; T M Dawson
Journal:  J Chem Neuroanat       Date:  1989 May-Jun       Impact factor: 3.052

10.  The D-1 dopamine receptor partial agonist, CY 208-243, exhibits antiparkinsonian activity in the MPTP-treated marmoset.

Authors:  J A Temlett; P N Chong; W H Oertel; P Jenner; C D Marsden
Journal:  Eur J Pharmacol       Date:  1988-11-01       Impact factor: 4.432

View more
  7 in total

1.  Motor activity following the administration of selective D-1 and D-2 dopaminergic drugs to MPTP-treated common marmosets.

Authors:  P A Löschmann; L A Smith; K W Lange; P Jähnig; P Jenner; C D Marsden
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  The effects of central aromatic amino acid DOPA decarboxylase inhibition on the motor actions of L-DOPA and dopamine agonists in MPTP-treated primates.

Authors:  S A Treseder; M Jackson; P Jenner
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

3.  Observational studies of dopamine D1 and D2 agonists in squirrel monkeys.

Authors:  S Rosenzweig-Lipson; P Hesterberg; J Bergman
Journal:  Psychopharmacology (Berl)       Date:  1994-09       Impact factor: 4.530

4.  Chronic treatment with the D1 receptor antagonist, SCH 23390, and the D2 receptor antagonist, raclopride, in cebus monkeys withdrawn from previous haloperidol treatment. Extrapyramidal syndromes and dopaminergic supersensitivity.

Authors:  H Lublin; J Gerlach; L Peacock
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

5.  Selective dopamine antagonist pretreatment on the antiparkinsonian effects of benzazepine D1 dopamine agonists in rodent and primate models of Parkinson's disease--the differential effects of D1 dopamine antagonists in the primate.

Authors:  K K Gnanalingham; A J Hunter; P Jenner; C D Marsden
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

6.  Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset.

Authors:  K K Gnanalingham; D D Erol; A J Hunter; L A Smith; P Jenner; C D Marsden
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

7.  The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease.

Authors:  K K Gnanalingham; A J Hunter; P Jenner; C D Marsden
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.